International trade issues, including free-trade agreements, import safety.
H.R. 2182, Generating Antibiotic Incentives Now (GAIN) Act. Prescription Drug User Fee Act (PDUFA)
Budget Control Act of 2011 (Became PL 112-25 on 8-2-11), Implementation.
H.R. 3630, Temporary Payroll Tax Cut Contribution Act of 2011
H.R. 3765, Temporary Payroll Tax Cut Contribution Act of 2011 (Became PL 112-78 on 12-23-11)
Budget issues, including Medicare Part D Rebates. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package. Independent Payment Advisory Board. Budget Control Act of 2011 (Became PL 112-25 on August 2, 2011), Implementation SEE CONTINUATION PAGE
H.R. 3630, Temporary Payroll Tax Cut Contribution Act of 2011
H.R. 3765, Temporary Payroll Tax Cut Contribution Act of 2011 (Became PL 112-78 on 12-23-11)
Duration: January 1, 2008
to
December 31, 2011
General Issues: Trade (Domestic & Foreign) , Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Pharmacy , Budget/Appropriations
Spending: about $808,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2008: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Kelly Bingel
Chief of Staff, Sen. Blanche Lincoln
David Castagnetti
Chief of Staff, Sen. Max Baucus
Elise Finley Pickering
Chief of Staff, Rep. Shaddegg; Exec. Dir. RPC
Allen Thompson
Sr. Prof Staff, House Cmte on Homeland Security
Sr Prof Staff, House Cmte on Homeland Security
Bruce Mehlman
Asst. Sec. of Commerce for Tech Policy
Stacey Rampy
Legislative Dir., Rep Eshoo
Dean Rosen
Health Policy Director, Sen. Bill Frist
David Thomas
Chief of Staff, Rep. Zoe Lofgren
Alex Vogel
Chief Counsel, Sen. Frist
Colette Desmarais
Health Policy Advisor, Sen. Grassley
Jonathan Hoganson
Policy Director, House Democratic Caucus;
Cynthia Brown
Chief of Staff, Rep. Ron Kind
Legislative Assistant, Rep. Bart Stupak
Brian Wild
Sr. Advisor, Office of Speaker John Boehner;
Dep Assistant for Leg Affairs, VP Cheney;
Chief of Staff, Rep. Pat Toomey;
Leg Assistant, Sen. Hank Brown
Dep. Assistant for Leg Affairs, VP Cheney;
Legislative Assistant, Sen. Hank Brown
Jamie Brown
Special Asst. to President for Leg. Affairs
Karin Hudson
Legislative Asst. Sen. Chris Dodd
Jonathan Hoganson (continued)
Legislative Director, Rep. Rahm Emanuel
Jamie Brown Hantman (Brown)
n/a
Elise Pickering
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2011
MEHLMAN VOGEL CASTAGNETTI, INC. terminated an engagement in which they represented ASTRAZENECA PHARMACEUTICALS on Jan. 13, 2012.
Original Filing: 300436977.xml
Lobbying Issues
International trade issues, including free-trade agreements, import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 2182, Generating Antibiotic Incentives Now (GAIN) Act. Prescription Drug User Fee Act (PDUFA)
Budget Control Act of 2011 (Became PL 112-25 on 8-2-11), Implementation.
H.R. 3630, Temporary Payroll Tax Cut Contribution Act of 2011
H.R. 3765, Temporary Payroll Tax Cut Contribution Act of 2011 (Became PL 112-78 on 12-23-11)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Budget issues, including Medicare Part D Rebates. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package. Independent Payment Advisory Board. Budget Control Act of 2011 (Became PL 112-25 on August 2, 2011), Implementation SEE CONTINUATION PAGE
H.R. 3630, Temporary Payroll Tax Cut Contribution Act of 2011
H.R. 3765, Temporary Payroll Tax Cut Contribution Act of 2011 (Became PL 112-78 on 12-23-11)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on Oct. 5, 2011.
Original Filing: 300410952.xml
Lobbying Issues
Tax issues, including repatriation, deferral and carried interest.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Health care reform: implementation issues, including pharmaceutical taxes, Medicaid changes, and comparative effectiveness.
H.R. 2182, Generating Antibiotic Incentives Now (GAIN) Act.
Prescription Drug User Fee Act (PDUFA)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Budget issues, including Medicare Part D Rebates. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package. Health reform implementation. Independent Payment Advisory Board. Budget Control Act of 2011 (Became PL 112-25 on August 2, 2011)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on July 11, 2011.
Original Filing: 300387325.xml
Lobbying Issues
Tax issues, including repatriation, deferral and carried interest.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Health care reform: implementation issues, including pharmaceutical taxes, Medicaid changes, and comparative effectiveness.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Budget issues, including Medicare Part D Rebates. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package. Health reform implementation. Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on April 13, 2011.
Original Filing: 300362653.xml
Lobbying Issues
Tax issues, including repatriation, deferral and carried interest.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Health care reform law (PL 111-148) -- implementation issues, including pharmaceutical taxes, Medicaid changes, and comparative effectiveness.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on Jan. 20, 2011.
Original Filing: 300347219.xml
Lobbying Issues
Tax issues, including repatriation, deferral and carried interest.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Health care reform law (PL 111-148) -- implementation issues, including pharmaceutical taxes, Medicaid changes, and comparative effectiveness.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on Oct. 14, 2010.
Original Filing: 300312381.xml
Lobbying Issues
Tax issues, including repatriation, deferral and carried interest.
H.R. 4213/S. 3551, American Jobs and Closing Tax Loopholes Act of 2010 (business tax provisions). (Became PL 111-205 on 7/22/10)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Health care reform law (PL 111-148) -- implementation issues, including pharmaceutical taxes, Medicaid changes, and comparative effectiveness.
(Continued on following page.)
H.R. 4213/S. 3551, American Jobs and Closing Tax Loopholes Act of 2010: health care provisions including drug pricing provisions, drug importation, physician payment (SGR), FMAP and COBRA. (Became PL 111-205 on 7/22/10)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act. Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage. Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on July 19, 2010.
Original Filing: 300291399.xml
Lobbying Issues
Tax issues, including repatriation, deferral and carried interest.
H.R. 4213/S. 3551, American Jobs and Closing Tax Loopholes Act of 2010 (business tax provisions).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.301, Physician Payments Sunshine Act of 2009; Grassley/Kohl Bill (regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis).
Health care reform law -- implementation issues, including pharmaceutical taxes, Medicaid changes, and comparative effectiveness.
H.R. 4213/S. 3551, American Jobs and Closing Tax Loopholes Act of 2010: health care provisions including drug pricing provisions, drug importation, physician payment (SGR), FMAP and COBRA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act.
Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage.
Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
S.301, Physician Payments Sunshine Act of 2009; Grassley/Kohl Bill (regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis).
Health care reform law -- implementation issues, including pharmaceutical taxes, Medicaid changes, and comparative effectiveness.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2010
In Q1, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on April 20, 2010.
Original Filing: 300267658.xml
Lobbying Issues
Tax issues, including repatriation and deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.301, Physician Payments Sunshine Act of 2009; Grassley/Kohl Bill (regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis).
Comparative Effectiveness: Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement. Information regarding company patient assistance program.
H.R.3200, America's Affordable Health Choices Act of 2009
S. 1796, America's Healthy Future Act of 2009
H.R. 3962, Affordable Health Care for America Act
H.R. 3590, Patient Protection and Affordable Care Act
H.R. 4872, The Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act.
Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage.
Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
H.R.3200, America's Affordable Health Choices Act of 2009
S. 1796, America's Healthy Future Act of 2009
H.R. 3962, Affordable Health Care for America Act
H.R. 3590, Patient Protection and Affordable Care Act
H.R. 4872, The Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on Jan. 11, 2010.
Original Filing: 300229026.xml
Lobbying Issues
Tax issues, including repatriation and deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.301, Physician Payments Sunshine Act of 2009; Grassley/Kohl Bill (regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis).
Comparative Effectiveness: Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement. Information regarding company patient assistance program.
H.R.3200, America's Affordable Health Choices Act of 2009
S. 1796, America's Healthy Future Act of 2009
H.R. 3962, Affordable Health Care for America Act
H.R. 3590, Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act.
Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage.
Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
H.R.3200, America's Affordable Health Choices Act of 2009
S. 1796, America's Healthy Future Act of 2009
H.R. 3962, Affordable Health Care for America Act
H.R. 3590, Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on Oct. 16, 2009.
Original Filing: 300206980.xml
Lobbying Issues
Tax issues, including repatriation and deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.301, Physician Payments Sunshine Act of 2009; Grassley/Kohl Bill (regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis).
Comparative Effectiveness: Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement. Information regarding company patient assistance program.
H.R.3200, America's Affordable Health Choices Act: Health care reform.
S. 1679, Affordable Health Choices Act: Health care reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act.
Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage.
Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on July 14, 2009.
Original Filing: 300176749.xml
Lobbying Issues
Tax issues, including repatriation and deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.301, Physician Payments Sunshine Act of 2009; Grassley/Kohl Bill (regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis).
Comparative Effectiveness: Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement. Information regarding company patient assistance program. Health care reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act.
Discussions and possible legislation amending Title XVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage.
Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on April 8, 2009.
Original Filing: 300145152.xml
Lobbying Issues
Tax issues, including repatriation and deferral.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.301, Physician Payments Sunshine act of 2009; Grassley/Kohl Bill (regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis).
Comparative Effectiveness: Senate proposal regarding use of Comparative effectiveness in health care coverage and/or reimbursement. Information regarding company patient assistance program. Health care reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act.
Discussions and possible legislation amending Title SVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage.
Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on Jan. 16, 2009.
Original Filing: 300124510.xml
Lobbying Issues
Tax issues, including extension of the Research and Development Tax Credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.558 and H.R.1424, The Mental Health Parity Act of 2007 (regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage).
S.2209, Physician Payments Sunshine act of 2007; Grassley/Kohl Bill (regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis).DOD Tricare issues, including retail pharmacy rebate and other related issues.
Comparative Effectiveness: Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement.
Genetic Information Nondiscrimination Act
Information regarding company patient assistance program
Health care reform
Legislation to fund cancer research, cancer supportive services and improve access to coverage under 340B program, regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act.
Discussions and possible legislation amending Title SVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage.S.301 and H.R.6331, The Medicare Improvements for Patients and Providers Act
S.3118, The Preserving Access to Medicare Act
Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Support of sufficient funding for the Food and Drug Administration to conduct meaningful and effective review of direct-to-consumer advertising.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $50,000. The report was filed on Oct. 18, 2008.
Original Filing: 300100279.xml
Lobbying Issues
Tax issues, including extension of the Research and Development Tax Credit.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
S.558 and H.R.1424, The Mental Health Parity Act of 2007 (regarding requirement for health plans and employers to provide mental health insurance coverage comparable to that of traditional medical coverage).
S.2209, Physician Payments Sunshine act of 2007; Grassley/Kohl Bill (regarding proposal to require pharmaceutical manufacturers to disclose provision of items of value to physicians on an annual basis).DOD Tricare issues, including retail pharmacy rebate and other related issues.
Comparative Effectiveness: Senate proposal regarding use of comparative effectiveness in health care coverage and/or reimbursement.
Genetic Information Nondiscrimination Act
Information regarding company patient assistance program
Health care reform
Legislation to fund cancer research, caner supportive services and improve access to coverage 340B program, regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
International trade issues, including free-trade agreements; import safety.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Discussions and possible legislation regarding possible increase in Medicaid program base rebate rate issues arising from Deficit Reduction Act.
Discussions and possible legislation amending Title SVIII, Part D (Medicare Part D) of SSA, including issues of "non-interference clause," protected classes of drugs, and Medicare Advantage.S.301 and H.R.6331, The Medicare Improvements for Patients and Providers Act
S.3118, The Preserving Access to Medicare Act
Legislation to address physician payments issues, including SGR and related provisions to Medicare package.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Support of sufficient funding for the Food and Drug Administration to conduct meaningful and effective review of direct-to-consumer advertising.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2008
In Q2, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $54,000. The report was filed on July 18, 2008.
Original Filing: 300074664.xml
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Budget/Appropriations Trade (Domestic & Foreign)
Lobbying Issues
S. 1082, Food & Drug Administration Revitalization Act
S. 2499, Medicare, Medicaid, and SCHIP Extension Act
H.R. 4/S.3, Medicare Prescription Drug Price Negotiation Act
Sunshine Act, Importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
In Q1, MEHLMAN VOGEL CASTAGNETTI, INC. lobbied for ASTRAZENECA PHARMACEUTICALS , earning $54,000. The report was filed on April 21, 2008.
Original Filing: 300055040.xml
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Budget/Appropriations Trade (Domestic & Foreign)
Lobbying Issues
S. 1082, Food & Drug Administration Revitalization Act
S. 2499, Medicare, Medicaid, and SCHIP Extension Act
H.R. 4/S.3, Medicare Prescription Drug Price Negotiation Act
Sunshine Act, Importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate